Sacituzumab tirumotecan (SKB264) is an antibody-drug conjugate (ADC) targeting TROP2 (trophoblast cell surface antigen 2), capable of releasing the active payload KL610023 within TROP2-positive tumour cells. an effective topoisomerase I inhibitor that induces DNA damage and leads to cell cycle arrest and apoptosis, for use in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).
Purity:
99.00%
CAS Number:
[2768350-77-0]
Target:
Antibody-Drug Conjugates (ADCs)|||TROP2
* VAT and and shipping costs not included. Errors and price changes excepted
